Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 2, 2016

DNAtrix begins Phase II trial of DNX-2401 and KEYTRUDA to treat recurrent glioblastoma

DNAtrix has announced that the first patients have been treated in a multicentre Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients suffering with recurrent glioblastoma.

DNAtrix has announced that the first patients have been treated in a multicentre Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients suffering with recurrent glioblastoma.

The CAPTIVE study is analysing the potential impact of DNX-2401 and KEYTRUDA in patients with recurrent glioblastoma, a disease for which there is neither a cure nor enough treatment.

Leading medical centres in the US and Canada are taking part in the study.

DNX-2401 is a conditionally replicative oncolytic adenovirus targeting and killing cancer cells, whilst leaving normal cells intact.

Several clinical studies have indicated that DNX-2401 has a favourable safety profile, strong tumour-killing potential and can trigger an anti-tumour immune response.

KEYTRUDA is a humanised monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

This activity boosts the T-cell response and leads to effective tumour destruction.

"Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease."

KEYTRUDA is currently approved in the US for advanced melanoma, metastatic non-small-cell lung cancer (NSCLC), and advanced head and neck squamous cell cancer (HNSCC).

DNAtrix CEO Frank Tufaro said: “Glioblastoma is a difficult disease to treat with conventional therapies.

“Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease.”

DNAtrix is a clinical stage biotechnology company developing virus-driven immunotherapies for cancer.


Image: MRI suggesting glioblastoma in a 15-year-old boy. Photo: courtesy of Christaras A / Wikipedia

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU